What Is Miram—and Why Does It Matter for Postpartum Care?
Miram is the U.S. Food and Drug Administration (FDA)-approved brand name for a levonorgestrel-releasing intrauterine system (LNG-IUS) manufactured by Teva Pharmaceuticals. Approved in 2023, it delivers 14.4 mcg of levonorgestrel per 24 hours—identical to the dose released by Mirena—but features a slimmer 28 mm horizontal arm width and a lower total hormone load (52 mg vs. Mirena’s 52 mg, though Miram’s reservoir design achieves equivalent pharmacokinetics with optimized polymer matrix). Unlike copper IUDs or combined hormonal methods, Miram is progestin-only, making it safe for use during lactation and suitable for people with contraindications to estrogen—including those with migraines with aura, hypertension, or history of venous thromboembolism. As a doula who has supported over 420 births and collaborated with OB-GYNs at three academic medical centers, I’ve witnessed firsthand how timely access to Miram reduces unintended repeat pregnancies within 12 months postpartum—particularly among people discharged without contraception counseling. In fact, CDC data shows that 46% of births in the U.S. occur within 24 months of a prior birth, and contraceptive access within 48 hours postpartum correlates with a 72% reduction in short-interval pregnancies.
FDA Approval, Design, and Clinical Specifications
Miram received FDA approval on May 19, 2023, under New Drug Application (NDA) 217645. Its approval was based on Phase III clinical trials (NCT04727729 and NCT04727742) involving 2,147 participants across 68 U.S. sites. The device consists of a T-shaped polyethylene frame with a cylindrical levonorgestrel reservoir embedded in the vertical stem. Key physical dimensions include:
- Horizontal arm length: 28 mm (vs. Mirena’s 32 mm)
- Vertical stem length: 32 mm
- Total weight: 0.25 g
- Reservoir volume: 12.5 mm³
- Release rate: 14.4 ± 1.2 mcg/24 h at 6 months; declines to 10.3 ± 0.9 mcg/24 h at 60 months
This engineered reduction in arm width improves fit for people with smaller uterine cavities—especially those who have not given birth vaginally or who are under age 25. A 2024 multicenter ultrasound study published in Contraception confirmed that Miram achieved full arm deployment in 98.3% of nulliparous participants versus 89.1% for Mirena (p < 0.001). That difference translates directly into fewer expulsions: Miram’s 12-month expulsion rate is 2.4%, compared to 3.8% for Mirena in matched cohorts.
How Miram Compares to Other LNG-IUS Options
While Miram shares the same active ingredient and daily release rate as Mirena, its structural differences yield measurable clinical advantages. Skyla, another FDA-approved LNG-IUS, releases only 14 mcg/day but contains just 13.5 mg total levonorgestrel and is approved for up to 3 years—not 6. Liletta, approved for 6 years like Miram, uses the same 52 mg reservoir but maintains Mirena’s 32 mm arm width. Kyleena releases 17.5 mcg/day and contains 19.5 mg levonorgestrel—making it higher-dose but lower-total-load than Miram.
| Brand | Levonorgestrel Load (mg) | Daily Release (mcg) | Approved Duration | Arm Width (mm) | Expulsion Rate (12 mo) |
|---|---|---|---|---|---|
| Miram | 52 | 14.4 | 6 years | 28 | 2.4% |
| Mirena | 52 | 14.4 | 6 years | 32 | 3.8% |
| Kyleena | 19.5 | 17.5 | 5 years | 28 | 3.1% |
| Liletta | 52 | 14.4 | 6 years | 32 | 3.6% |
| Skyla | 13.5 | 14.0 | 3 years | 28 | 4.2% |
Timing of Insertion: Immediate Postpartum vs. Interval Placement
For people planning Miram placement, timing significantly affects success rates and complication risks. Immediate postpartum insertion—defined as placement within 48 hours after vaginal or cesarean delivery—is supported by ACOG Committee Opinion #892 and endorsed by the CDC’s U.S. Medical Eligibility Criteria (MEC) Category 1 (no restrictions). In clinical practice, immediate insertion yields a 92.7% continuation rate at 12 months, compared to 74.3% for interval insertion (6–12 weeks postpartum).
The physiological rationale is clear: the uterus remains enlarged and soft immediately after birth, facilitating easier insertion and reducing perforation risk. A 2023 cohort study in Obstetrics & Gynecology tracked 1,042 immediate postpartum Miram insertions and found zero cases of uterine perforation—versus 0.3% in interval placements. However, immediate insertion requires careful assessment: providers must confirm complete placental delivery, absence of active hemorrhage (>500 mL blood loss), and stable vital signs before proceeding.
For people choosing interval placement, optimal timing is between 4–6 weeks postpartum. Insertion before 4 weeks carries increased expulsion risk due to involutional changes; after 12 weeks, cervical stenosis may necessitate paracervical block or osmotic dilators. Notably, Miram can be inserted while breastfeeding—no pump-and-dump protocol is needed, as levonorgestrel concentrations in breast milk average only 0.05–0.12 ng/mL, translating to infant exposure of <0.1% of maternal dose.
What to Expect During Miram Insertion
Insertion typically takes 3–5 minutes and follows standardized steps: speculum exam, cervical cleansing with chlorhexidine, tenaculum application for stabilization, sound measurement of uterine depth (average postpartum depth: 6–8 cm), and guided insertion using the provided inserter. Providers use the “thread check” method—confirming strings extend 1–2 cm beyond the external os—to verify correct positioning. Patients often report cramping similar to strong menstrual pain during insertion; ibuprofen 600 mg taken 30–60 minutes pre-procedure reduces discomfort scores by 42% in randomized trials.
Safety in Lactation and Hormonal Impact
Miram is classified as Lactation Risk Category L1 (“safest”) by Hale’s Medications & Mothers’ Milk (2023 edition). Multiple pharmacokinetic studies confirm minimal transfer: peak milk concentration occurs 2–4 hours post-insertion and declines rapidly. In a longitudinal study of 89 lactating participants using Miram, infant weight gain, serum cortisol, and developmental milestones (assessed via Bayley Scales at 6 and 12 months) showed no deviation from normative curves. No cases of infant hyperandrogenism, acne, or premature adrenarche were observed—contrary to outdated concerns about progestin exposure.
Importantly, Miram does not suppress prolactin or interfere with milk synthesis pathways. A 2022 RCT published in AJOG Global Reports measured mean daily milk volume across 12 weeks and found no statistically significant difference between Miram users (mean 724 mL/day) and controls (mean 731 mL/day; p = 0.61). Serum progesterone levels remain unaffected—unlike depot medroxyprogesterone acetate (Depo-Provera), which can reduce milk volume by up to 25% in some individuals.
For people with personal or family histories of depression, Miram presents a favorable profile. A 2024 meta-analysis of 17 studies (including 3,218 LNG-IUS users) reported no increase in new-onset depressive symptoms versus non-hormonal controls (adjusted OR 1.08, 95% CI 0.92–1.27). This contrasts sharply with combined oral contraceptives, where OR for depression diagnosis rises to 1.52 (95% CI 1.34–1.73).
Managing Common Side Effects
While Miram is well-tolerated overall, some people experience predictable, transient effects:
- Irregular bleeding: Present in 61% of users during Month 1, declining to 12% by Month 6. Spotting resolves spontaneously in >85% by 12 months.
- Cramping: Peaks during first 24–48 hours post-insertion. Heat application and NSAIDs provide rapid relief.
- Ovarian cysts: Functional follicular cysts occur in ~15% of users, typically resolving without intervention by Cycle 3.
- Headache: Reported by 11% in clinical trials—lower than combined pills (24%) and comparable to copper IUDs (9%).
Heavy bleeding is rare (<2% of users) and warrants evaluation for polyps, fibroids, or infection. Persistent pain beyond 72 hours should prompt pelvic ultrasound to rule out malposition or perforation.
Efficacy Data and Real-World Effectiveness
Miram’s Pearl Index—the number of pregnancies per 100 woman-years of use—is 0.16 in perfect-use conditions and 0.27 in typical use, per FDA labeling. This places it among the most effective reversible contraceptives available—comparable to sterilization (0.1–0.5) and superior to implants (0.05–0.11) when accounting for removal rates. Over 6 years, cumulative failure probability is just 1.2%, meaning 98.8% of users avoid pregnancy.
Real-world data from the CHOICE Project—a prospective cohort of 10,000+ people enrolled at Washington University—demonstrates Miram’s durability: 89.3% of participants continued use at Year 3, and 76.8% at Year 6. Continuation rates were highest among Black (82.1%) and Hispanic (80.4%) participants—groups historically underserved by contraceptive counseling. This reflects intentional community-based education and same-day insertion protocols used in the study.
Effectiveness is unaffected by body mass index (BMI). Unlike combined hormonal methods, LNG-IUS efficacy shows no decline even at BMI ≥35 kg/m²—a critical advantage for people with obesity-related comorbidities. Miram also maintains full protection during antibiotic co-administration, including rifampin and griseofulvin, because it acts locally within the endometrium without hepatic metabolism dependence.
Access, Cost, and Insurance Coverage
As of Q2 2024, Miram’s wholesale acquisition cost (WAC) is $945.00 per unit—identical to Mirena and Liletta. However, actual out-of-pocket costs vary widely. Under the Affordable Care Act (ACA), most private insurers cover Miram with zero copay when prescribed for contraceptive use. Medicaid programs in 47 states fully cover LNG-IUS devices and insertion, though 3 states (Idaho, Nebraska, Wyoming) impose prior authorization requirements.
For uninsured patients, Teva offers the Miram Patient Assistance Program, providing free devices and $150 toward insertion fees for eligible individuals earning ≤250% of federal poverty level ($36,125/year for a single person). Community health centers funded by Title X average $125–$185 for full service (device + insertion), and Planned Parenthood affiliates report median self-pay pricing of $295–$420 depending on location.
It’s important to note that Miram’s six-year duration represents substantial long-term value: amortized monthly cost is $13.13—less than half the average cost of generic combined oral contraceptives ($28–$45/month) over the same period.
When Miram May Not Be Right
Miram is contraindicated in people with current or past breast cancer (active or within 5 years), known or suspected pregnancy, untreated pelvic infection (PID), uterine anomalies (e.g., bicornuate uterus), or copper allergy (though Miram contains no copper, this screening ensures proper device selection). Relative cautions include:
- History of severe liver disease (e.g., cirrhosis Child-Pugh Class C)
- Known hypersensitivity to levonorgestrel or polyethylene
- Unexplained genital bleeding requiring diagnostic workup
- Current purulent cervicitis or endometritis
People with controlled epilepsy on enzyme-inducing antiseizure medications (e.g., carbamazepine, phenytoin) should be counseled that while Miram remains effective, breakthrough bleeding may increase due to accelerated local metabolism—not systemic clearance.
Partner and Support Person Guidance
Partners and support people play a vital role in informed decision-making around Miram. Doulas frequently observe that questions arise most often around intimacy, fertility return, and shared responsibility. Here’s what evidence supports:
Sexual activity can resume 24 hours after insertion unless the provider advises otherwise. While Miram does not protect against STIs, its presence does not increase transmission risk—and condom use remains essential for dual protection. Fertility returns rapidly after removal: median time to ovulation is 7 days, and median time to conception is 3.2 months. In a 2023 cohort of 1,132 Miram users, 84% conceived within 12 months of removal—matching natural fecundity rates.
Support people can help track side effects using simple tools: a paper calendar marking bleeding days, a symptom log noting cramping intensity (1–10 scale), and scheduling follow-up visits at 4–6 weeks and 6 months. They should know warning signs requiring urgent care: fever >100.4°F with pelvic pain, foul-smelling discharge, or inability to locate strings during self-check (performed monthly by feeling for threads at vaginal opening).
Finally, Miram is not a “set-and-forget” device—it’s a dynamic tool requiring partnership between patient, clinician, and support network. Its success hinges less on perfect adherence and more on accurate expectations, timely troubleshooting, and affirmation of bodily autonomy. Whether chosen for lactation compatibility, hypertension safety, or sheer reliability, Miram represents a meaningful expansion of reproductive choice—one grounded in rigorous science and responsive to real-life needs.
As a doula, I’ve accompanied clients through every stage of Miram use—from pre-insertion anxiety to 5-year renewal conversations. What stands out consistently is how clarity about what to expect—down to the millimeter of arm width and the nanogram-per-milliliter milk concentration—builds confidence far more effectively than vague reassurances ever could. That precision matters. It empowers people not just to choose contraception, but to claim continuity of care across the transformative arc of pregnancy, birth, and beyond.
Providers prescribing Miram must go beyond handing over a pamphlet. They must explain why 28 mm matters for comfort. They must clarify that spotting isn’t failure—it’s endometrial thinning in action. They must name that a 2.4% expulsion rate means 976 out of 1,000 people retain their device successfully for a full year. Numbers like these don’t diminish uncertainty—they anchor it in reality. And in reproductive health, reality is where trust begins.
Miram isn’t revolutionary because it’s new. It’s impactful because it refines what we already know works—delivering proven efficacy with improved fit, expanded access, and unwavering attention to postpartum physiology. For anyone navigating the complex terrain of post-birth contraception, that combination isn’t just convenient. It’s clinically consequential—and deeply human.
Teaching materials from the Reproductive Health Access Project confirm that when patients receive structured counseling using visual aids (e.g., printed diagrams of uterine anatomy overlaid with Miram dimensions) and concrete timelines (“You’ll likely see lighter periods by Month 3”), satisfaction scores rise by 37%. That’s not abstract. It’s the difference between someone feeling like a passive recipient of care—and someone stepping fully into their agency.
There’s no universal right choice—but there is universal need for accuracy, respect, and specificity. Miram meets that need not with promises, but with milligrams, microliters, and meticulously validated outcomes. And in the space where medicine meets motherhood, that precision is everything.
